Sartorius AGSARTF 84 PS Ratio is 3.56 as of Jun. 27, 2026, which is 31% below its 10-year median of 5.14. GuruFocus rates SARTF with a GF Score™ of 84/100 and a GF Value™ of $274.29 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Sartorius AG ranks worse than 59.2% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Sartorius AG's share price is $212.80.
Sartorius AG's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $59.80. Hence, Sartorius AG's PS Ratio for today is 3.56.
The historical rank and industry rank for Sartorius AG's PS Ratio or its related term are showing as below:
SARTF'
s PS Ratio Range Over the Past 10 Years
Min: 2.46 Med: 5.14 Max: 18.32
Current: 3.72
During the past 13 years, Sartorius AG's highest PS Ratio was 18.32. The lowest was 2.46. And the median was 5.14.
SARTF's PS Ratio is ranked worse than 59.2% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.86
vs SARTF: 3.72
Sartorius AG revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Sartorius AG was 3.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -5.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 5.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 14.30% per year.
During the past 13 years, Sartorius AG's highest 3-Year average Revenue per Share Growth Rate was 31.70% per year. The lowest was -5.70% per year. And the median was 8.10% per year.
Back to Basics: PS Ratio
Sartorius AG (OTCPK:SARTF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Sartorius AG PS Ratio Related Terms
Sartorius AG PS Ratio Historical Data
* Premium members only.
The historical data trend for Sartorius AG's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sartorius AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's PS Ratio distribution charts can be found below:
* The bar in red indicates where Sartorius AG's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Sartorius AG's PS Ratio for today is calculated as
Sartorius AG's Share Price of today is $212.80. Sartorius AG's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $59.80.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Sartorius AG (SARTF) has a PS Ratio of 3.56 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Sartorius AG and its competitors. This is 31% below median its historical median of 5.14. Over the past decade, Sartorius AG's PS Ratio has ranged from 2.46 to 18.32. According to the industry distribution chart, Sartorius AG ranks #476 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 59.2%.
Is Sartorius AG's PS Ratio too high?
Sartorius AG's current PS Ratio of 3.56 is 31% below median its 10-year median of 5.14. Over the past 10 years, this metric has ranged from a low of 2.46 to a high of 18.32. The Medical Devices & Instruments industry median PS Ratio is 2.86. Sartorius AG's value of 3.56 is 24.5% above this industry median. Based on the distribution chart, Sartorius AG ranks #476 out of 804 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sartorius AG has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's PS Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #476 out of 804 companies for PS Ratio. This places Sartorius AG in the lower half of its industry. The industry median PS Ratio is 2.86. Sartorius AG's value of 3.56 is 24.5% above this benchmark. Historically, Sartorius AG's own PS Ratio has ranged from 2.46 to 18.32 over the past decade. While the company's 10-year median is 5.14 vs. the industry median of 2.86, Sartorius AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.86, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current PS Ratio of 3.56 is 24.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current PS Ratio is 3.56, which is 31% below median its own 10-year median of 5.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $274.29, compared to a current price of $212.80 — trading 22.4% below its estimated fair value. The current PS Ratio is 3.56, which is 31% below median its 10-year median of 5.14 and 24.5% above the Medical Devices & Instruments industry median of 2.86. Sartorius AG's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Sartorius AG (SARTF), the current PS Ratio is 3.56 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 22.4% below its estimated GF Value™ of $274.29.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
PS Ratio: 3.56 (31% below median its 10-year median of 5.14)
GF Value™: $274.29 vs. price of $212.80 (22.4% below fair value)
Industry Position: 24.5% above the Medical Devices & Instruments median (#476 of 804)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
84GF Score
Get the complete analysis for SARTF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
